Latest Boehringer Ingelheim Corporation Stories
Findings presented at American Heart Association's Scientific Sessions add to growing body of data supporting safety and effectiveness of PRADAXA RIDGEFIELD, Conn., Nov.
- RE-VERSE AD(TM) is being conducted in more than 35 countries with aim to enroll 250 patients RIDGEFIELD, Conn., Nov. 10, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
- Poster on research about investigational, specific antidote for PRADAXA also to be presented RIDGEFIELD, Conn., Nov. 10, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
RIDGEFIELD, Conn., Nov. 3, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced that the U.S.
Largest observational study of a newer oral anticoagulant, with more than 134,000 elderly patients, published in Circulation RIDGEFIELD, Conn., Nov. 3, 2014 /PRNewswire/ -- A U.S.
Data for the co-administration of Spiriva® HandiHaler® (tiotropium bromide inhalation powder) + Striverdi® Respimat® (olodaterol) Inhalation Spray presented at CHEST 2014 RIDGEFIELD,
RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 21, 2014 /PRNewswire/ -- The U.S.
-- LUME-COLON 1 will evaluate the efficacy and safety of nintedanib in specific patients with metastatic colorectal cancer (mCRC) whose disease has progressed on previous treatment
Boehringer Ingelheim launches comprehensive support resources for people with idiopathic pulmonary fibrosis RIDGEFIELD, Conn., Oct.
Company to make OFEV available to IPF community within 10 days, along with comprehensive patient support resources RIDGEFIELD, Conn., Oct.
- In medieval musical notation, a sign or neume denoting a shake or trill.